Skip to main content

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Oppenheimer 34th Annual Healthcare Life Sciences Conference
Fireside Chat: Wednesday, February 14, 2024 at 10:00 am ET
Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.57
+2.30 (1.12%)
AAPL  273.45
+7.27 (2.73%)
AMD  210.21
+13.61 (6.92%)
BAC  49.90
-1.17 (-2.30%)
GOOG  309.41
-2.28 (-0.73%)
META  636.05
-1.20 (-0.19%)
MSFT  386.50
+2.03 (0.53%)
NVDA  191.93
+0.38 (0.20%)
ORCL  145.41
+4.09 (2.90%)
TSLA  407.11
+7.28 (1.82%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.